BioLargo (BLGO) AI Stock Analysis

• Market Cap: $49.05M
• Dividend Yield: N/A
• Average Volume (3M): 570.01K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.40
• Revenue Growth: -41.57%
• EPS Growth: -345.83%
• Country: US
• Employees: 40
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): -0.02
• Shares Outstanding: 308,989,040
• 10 Day Avg. Volume: 632,227
• 30 Day Avg. Volume: 570,010
• PEG Ratio: 0.69
• Price to Book (P/B): 6.40
• Price to Sales (P/S): 3.19
• P/FCF Ratio: -12.75
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: 5.54
• Enterprise Value/Gross Profit: 11.89
• Enterprise Value/Ebitda: -5.26
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $0.18 ▼(-2.22% Downside)

BioLargo's overall stock score is primarily impacted by its financial performance, which shows strong revenue growth but persistent profitability and cash flow challenges. Technical analysis indicates short-term bullish momentum, but valuation concerns and legal issues with Pooph weigh heavily on the stock's outlook.

Positive Factors

Revenue Growth

Strong revenue growth over recent years indicates successful market penetration and demand for BioLargo's environmental technologies.

Technological Advancements

Third-party validation of battery technology enhances credibility and opens potential new revenue streams through industrial applications.

Strategic Partnerships

Strategic partnerships, like with Clyra Medical, expand BioLargo's market reach and potential revenue, supporting long-term growth.

Negative Factors

Legal Disputes

Ongoing legal disputes with Pooph create financial uncertainty and distract management from core business operations.

Negative Cash Flow

Persistent negative cash flow indicates operational inefficiencies and reliance on external financing, posing long-term financial risks.

Revenue Decline

Significant revenue decline due to Pooph's credit loss suggests vulnerability in revenue streams and highlights dependency on key clients.

BioLargo Business Overview & Revenue Model

Company Description

BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

How the Company Makes Money

BioLargo generates revenue through multiple streams, primarily from the sale of its proprietary environmental technologies and products. Key revenue sources include direct sales of its AOS system and related services to industrial and municipal clients, as well as licensing agreements with partners for the use of its technologies. The company also engages in research and development contracts, providing tailored solutions that meet specific client needs. Strategic partnerships with organizations and governmental agencies enhance its market reach and credibility, contributing to its potential earnings. Additionally, BioLargo explores opportunities for joint ventures and collaborations that can further expand its product offerings and customer base.

BioLargo Financial Statement Overview

Summary

BioLargo shows strong revenue growth but remains unprofitable with ongoing operational and cash flow challenges. The balance sheet is stable with a healthy equity ratio, but liquidity risks persist due to negative cash flows.

Income Statement

BioLargo has demonstrated significant revenue growth, increasing from $1.86M in 2019 to $17.78M in 2024, showing a strong upward trajectory. However, the company remains unprofitable with consistent net losses, including a net loss of $2.40M in 2024. The gross profit margin has improved but remains volatile. EBIT and EBITDA margins remain negative, indicating operational challenges.

Balance Sheet

BioLargo's financial stability is supported by a strong equity position with a debt-to-equity ratio significantly improved over the years, now at 0.17. The equity ratio is healthy at 84.18%. However, the company has high leverage in earlier years and a history of negative net debt, indicating potential liquidity risks.

Cash Flow

Operating cash flow has been consistently negative, reflecting ongoing operational cash burn. Free cash flow growth has not been positive, and the free cash flow to net income ratio remains challenging. While financing activities have supported cash needs, sustained negative cash flows pose a risk to long-term financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.81M	17.78M	12.23M	5.88M	2.53M	2.43M
Gross Profit	5.03M	7.85M	6.15M	2.86M	1.10M	1.23M
EBITDA	-11.37M	-4.06M	-4.19M	-5.10M	-6.70M	-7.83M
Net Income	-9.84M	-2.40M	-3.50M	-4.50M	-7.38M	-10.47M
Balance Sheet
Total Assets	9.13M	10.51M	8.21M	4.86M	3.02M	4.94M
Cash, Cash Equivalents and Short-Term Investments	4.55M	3.55M	3.54M	1.85M	962.00K	716.00K
Total Debt	1.49M	2.55M	1.70M	1.47M	1.13M	2.67M
Total Liabilities	2.46M	4.46M	4.00M	2.85M	2.09M	5.18M
Stockholders Equity	6.58M	8.85M	6.84M	4.88M	4.65M	3.86M
Cash Flow
Free Cash Flow	-8.60M	-4.44M	-2.84M	-3.03M	-3.97M	-4.18M
Operating Cash Flow	-8.62M	-3.21M	-2.37M	-2.76M	-3.94M	-4.15M
Investing Cash Flow	391.00K	-1.32M	-478.00K	-271.00K	-34.00K	-123.00K
Financing Cash Flow	8.86M	4.44M	4.66M	3.96M	4.23M	4.34M

BioLargo Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.18
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Neutral. The current price of 0.18 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.17, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.18 is Neutral, neither overbought nor oversold. The STOCH value of 36.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BLGO.

BioLargo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ASIX	59 Neutral	$428.48M	8.30	6.62%	3.83%	-5.05%	35.01%
TROX	57 Neutral	$608.84M	―	-18.65%	7.74%	-7.81%	-334.15%
FF	54 Neutral	$139.29M	―	-18.09%	7.55%	-49.82%	-195.74%
RYAM	49 Neutral	$417.44M	―	-78.11%	―	-9.75%	-386.63%
BLGO	48 Neutral	$49.05M	-12.25	-129.84%	―	-41.57%	-345.83%
ORGN	42 Neutral	$66.57M	―	-21.13%	―	-28.47%	16.83%

BioLargo Corporate Events

BioLargo Officers Convert Salary to Common Stock

On November 14, 2025, BioLargo Inc. announced that two of its officers converted $99,901 of unpaid salary and unreimbursed business expenses into 624,383 shares of common stock at a price of $0.16 per share. These shares are subject to a Lock-Up Agreement, restricting their sale until the company achieves certain financial milestones, such as reporting gross revenue of at least $40 million, reaching a market capitalization of $300 million, or undergoing a change in control.

BioLargo to Present Investor Webcast on Nov 14

BioLargo, Inc. announced that it will present a slide deck during an investor webcast scheduled for November 14, 2025. The presentation is part of the company’s ongoing efforts to engage with investors and provide updates on its operations, although the information shared will not be incorporated into any SEC filings. This move reflects BioLargo’s strategy to maintain transparency and communication with stakeholders while managing regulatory obligations.

BioLargo Participates in LD Micro Main Event XIX

BioLargo, Inc. announced its participation in the LD Micro Main Event XIX, held on October 20 at the Hotel del Coronado in San Diego, California. The company presented slides during this event, although the information shared is not considered filed with the SEC and is not subject to certain liabilities under the Securities Exchange Act of 1934.

BioLargo Revokes Pooph’s License Over Unpaid Royalties

On September 25, 2025, BioLargo announced the revocation of Pooph Inc.’s license to use its technology due to Pooph’s failure to meet contractual obligations, including $3.8 million in unpaid royalties and product invoices. This decision impacts Pooph’s ability to market and sell products based on BioLargo’s patents and proprietary information, significantly affecting Pooph’s operations. BioLargo remains committed to advancing its technology portfolio and protecting its intellectual property, despite the termination of the business relationship with Pooph.